

May 31, 2005



The **BANK**  
of **NEW YORK**

**SECURITIES SERVICING**  
**DEPOSITARY RECEIPTS**

## Corporate Action

**ATTENTION: International Research, Sales, Trading and Operations Staff**

### RATIO CHANGE

#### TRINITY BIOTECH PLC

|                      | OLD       | NEW                      |
|----------------------|-----------|--------------------------|
| <b>Symbol:</b>       | TRIB      | UNCHANGED                |
| <b>CUSIP Number:</b> | 896438108 | 896438306                |
| <b>Exchange:</b>     | NASDAQ    | UNCHANGED                |
| <b>Ratio:</b>        | 1:1       | 1 ADR: 4 ORDINARY SHARES |

Trinity Biotech plc will change the ratio of its ADR facility from one (1) ADR equaling (1) ordinary share to one (1) ADR equaling four (4) ordinary shares. The effective date for the transaction is on the opening of business on **Thursday, June 2, 2005**.

As a result of the ratio change, for every **four (4) ADRs** held under the old CUSIP number **896438108**, investors will **receive one (1) new ADR** under the **NEW** CUSIP number **896438306**.

There will be a mandatory exchange for ADR holders of Old CUSIP # 896438108 to receive their entitlement to the New CUSIP# 896438306.

To learn more about ADRs and issuer programs, please call our marketing desks:

**New York**

**Sell-side**

Jason L. Paltrowitz

Vice President

jpaltrowitz@bankofny.com

212 815 2077 Telephone

**New York**

**Buy-side**

Joseph Flannery

Assistant Treasurer

jflannery@bankofny.com

212 815 3095 Telephone

**London**

**Sell-side / Buy-side**

Joseph Oakenfold

Assistant Treasurer

joakenfold@bankofny.com

44 207 964 6419 Telephone

This information and data is provided for general informational purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. The Bank of New York does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market value loss on the sale or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. **Please also see "Terms of Use."**